Evidence map›Paper›PMID 41023133›Full record

ArticleExperimental & molecular medicine2025

PAK4 phosphorylates cyclin-dependent kinase 2 to promote the G

Hwang Chan Yu, Su Hyeon Park, Hye Jin Jo, Hyunchae Sim, Mi Rin Lee, Gahee Kim, So-Young Park, Yoonji Lee, Eun Ju Bae, Byung-Hyun Park

Abstract read
In one paragraph

Article in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hwang Chan Yu *Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Su Hyeon Park *Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Hye Jin JoSchool of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea.
Hyunchae SimSchool of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Mi Rin LeeDepartment of Surgery, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
Gahee KimCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
So-Young ParkDepartment of Physiology, College of Medicine, Yeungnam University, Daegu, Republic of Korea.
Yoonji LeeCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea. yoonjilee@cau.ac.kr.ORCID http://orcid.org/0000-0002-2494-5792
Eun Ju BaeSchool of Pharmacy and Institute of New Drug Development, Jeonbuk National University, Jeonju, Republic of Korea. ejbae7@jbnu.ac.kr.ORCID http://orcid.org/0000-0003-1693-8290
Byung-Hyun ParkGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea. bhparkut@kaist.ac.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

p21-activated kinase 4 (PAK4), a member of the PAK family (PAK1-6), was initially recognized for its role in tumor development. Recently, we discovered PAK4's involvement in triacylglycerol lipolysis in adipocytes. However, its function in adipogenesis remains unclear. Here we show that PAK4 plays a critical role in adipocyte differentiation. Following adipogenic stimulation, PAK4 protein levels increased. Knockdown of PAK4 in 3T3-L1 preadipocytes or human stromal vascular cells, as well as pharmacological inhibition of PAK4 in 3T3-L1 cells, impaired adipogenesis, as indicated by reduced expression of adipocyte marker genes and decreased lipid accumulation. Mechanistically, PAK4 phosphorylated cyclin-dependent kinase 2 at serine 106, a critical step for CCAAT/enhancer-binding protein β expression during mitotic clonal expansion. Consistent with these findings, preadipocyte-specific Pak4-knockout mice exhibited reduced fat mass and smaller adipocytes. These results reveal PAK4 as a crucial regulator of adipogenesis and, together with its inhibitory role in triacylglycerol lipolysis, further underscore its potential as a therapeutic target for obesity treatment.

Indexed as

AdipogenesisG1 Phasep21-Activated Kinases3T3-L1 CellsAdipocytesAnimalsCell DifferentiationHumansMiceMice, KnockoutPhosphorylationp21-Activated KinasesPAK4 protein, humanPak4 protein, mouse

Identifiers

PMID41023133
PMCPMC12508475

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.